Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 22nd Feb 2013 07:12

Antofagasta: RBC upgrades from underperform to outperform.Ashmore Group: Citigroup raises target price from 330p to 355p upgrading to neutral. JP Morgan ups target price from 361p to 413p and maintains a neutral rating.Babcock International: Citigroup revises target price from 965p to 1185p and keeps its buy recommendation.BAE Systems: Deutsche Bank takes target price from 360p to 375p maintaining a buy recommendation. JP Morgan increases target price from 330p to 360p and retains a neutral rating.Barclays: Investec shifts target price from 340p to 345p and upgrades from hold to buy.BP: Canaccord Genuity downgrades from buy to hold with a target price of 500p.Bumi: JP Morgan reiterates underweight. Liberum reinitiates coverage at buy.British Sky Broadcasting: HSBC ups target price from 520p to 600p keeping an underweight rating.Capita Group: Citigroup moves target price from 870p to 990p, while leaving its buy recommendation unchanged.Chariot Oil & Gas: Jefferies ups target price from 36p to 50p and upgrades from hold to buy. Merchant Securities cuts target price from 29.20p to 20.60p, while reiterating a hold recommendation.CSR: UBS raises target price from 330p to 450p, while retaining a neutral rating. Deutsche Bank revises target price from 255p to 300p, while staying with its sell recommendation. JP Morgan takes target price from 450p to 475p and reiterates an overweight rating. Canaccord Genuity moves target price from 370p to 475p and keeps a buy recommendation.Drax Group: Goldman Sachs downgrades from buy to neutral.Filtrona: UBS increases target price from 600p to 660p and keeps a buy recommendation.Fresnillo: Societe Generale initiates with a target price of 1200p and a sell recommendation.GlaxoSmithKline: Jefferies moves target price from 1500p to 1550p and maintains a hold recommendation.Go-Ahead Group: HSBC revises target price from 1415p to 1485p, while staying with an overweight rating.G4S: HSBC shifts target price from 260p to 270p and downgrades to underweight.Halfords Group: UBS lowers target price from 290p to 280p and retains a sell recommendation.HSBC Holdings: Credit Suisse moves target price from 750p to 760p and keeps an outperform rating.Informa: Deutsche Bank shifts target price from 600p to 620p and leaves its buy recommendation unaltered. Citigroup takes target price from 520p to 550p reiterating a buy rating. Westhouse Securities ups target price from 493p to 525p and upgrades from neutral to add. Canaccord Genuity raises target price from 500p to 560p maintaining its buy recommendation. Investec increases target price from 495p to 520p keeping a hold recommendation.InterContinental Hotels Group: Citigroup increases target price from 1900p to 2200p retaining its buy recommendation.Interserve: Westhouse Securities raises target price from 432p to 537p, while downgrading from buy to add.Johnson Matthey: Morgan Stanley reduces target price form 2300p to 2200p retaining an underweight rating.Kingfisher: HSBC cuts target price from 340p to 335p and keeps its overweight rating.Lancashire: Nomura increases target price from 826p to 906p not altering its neutral rating.Millennium & Copthome: Credit Suisse moves target price from 524p to 542p and retains its neutral rating.Mondi: UBS ups target price from 720p to 840p, while leaving its neutral rating unchanged.Netplay: Merchant Securities initiates with a target price of 20p and a buy recommendation.New World Resources: JP Morgan shifts target price from 150p to 160p leaving its underweight rating unaltered.Old Mutual: JP Morgan raises target price from 186p to 209p, while downgrading to neutral.Pendragon: Panmure Gordon shifts target price from 15p to 19p and still recommends selling.Restaurant Group: Citigroup revises target price from 400p to 450p, while the buy recommendation is kept.REXAM: Credit Suisse shifts target price from 545p to 555p and stays with its neutral rating. Oriel Securities ups target prcie from 540p to 570p maintaining a buy recommendation.Sainsbury: Citigroup raises target price from 315p to 385p upgrading to buy.Serco Group: Citigroup shifts target price from 670p to 680p reiterating a buy recommendation.Shire: Morgan Stanley moves target price from 2350p to 2400p keeping an overweight rating.Spectris: N+1 Singer takes target price from 2135p to 2415p, while reiterating a hold recommendation. Investec ups target price from 2400p to 2575p and stays with its hold rating.Sports Direct International: Citigroup increases target price from 470p to 530p and still recommends buying.Whitbread: Citigroup raises target price from 2400p to 2675p and leaves its neutral rating unchanged. JP Morgan revises target price from 2650p to 2700p maintaining an overweight rating. Panmure Gordon ups target price from 1994p to 2500p, while reiterating a hold recommendation.William Hill: Jefferies raises target price from 370p to 500p keeping a buy recommendation.Xaar: Investec starts with a target price of 350p and a buy recommendation.
More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.